Yue Xiang Yue Health Submits IPO Filing in March 2026
TG ImmunoPharma
ImmunoPharma Developer
E-Health Now
Lifecycle Intelligent Health Management Service Provider
Healthgen Biotech
Research and Product Developer of Plant-derived Recombinant Protein Expression Technology
Century Healthcare
Medical Device Manufacturer, R&D, and Distributor
Click to follow?｜Focus on Global Biomedical Investment
In March, the industry's grand event BIOCHINA 2026 opened in Suzhou. Mr. Zhu Pai, CEO of E-Front Capital, was invited to attend and participated in the roundtable forum "LP-GP Ecosystem: 'Synergy' in Policy, Capital, and Innovation" on the 13th, engaging in an in-depth dialogue with industry peers. Meanwhile, the companies invested by E-Front Capital also shone brightly at this conference: TGI and other enterprises made significant appearances, showcasing the cutting-edge strength of China's innovative pharmaceutical companies to the industry.
Outside the conference, numerous invested companies of Edge Capital are also making significant progress in their respective fields, achieving key breakthroughs one after another and demonstrating vigorous development momentum.
01
Progress of Portfolio Companies' IPOs and Financing
E-Health Now
· AI Agent Reconstructs the Ecosystem of Healthcare Management Services
E-Health Now
· AI Agent Reconstructs the Ecosystem of Healthcare Management Services
Recently, E-Health Now, a leading artificial intelligence digital health service technology group in China, officially announced the completion of a financing round worth hundreds of millions of RMB.DThis round of financing was jointly led by EF Capital, Yahelon, Ventech China, and Fengqiao Capital.
02
Clinical and Commercial Dynamics of Invested Companies
Healthgen Biotech
· Aflibercept® Phase IV Clinical Trial Completes First Dose Administration
Recently, Healthgen Biotech's recombinant human albumin (rice) Oufumin® "In Hypoalbuminemia and/or insufficient blood volume requiring emergency treatment in patients for safety and efficacy"IV The first patient was enrolled and the first dose was administered in the Phase I clinical study.IV Entering the substantive clinical research stage.
Century Healthcare
· Completed by multiple hospitalsInnermedical's Endoscopic Surgery
Healthgen Biotech
· Aflibercept® Phase IV Clinical Trial Completes First Dose Administration
Recently, Healthgen Biotech's recombinant human albumin (rice) Oufumin® "In Hypoalbuminemia and/or insufficient blood volume requiring emergency treatment in patients for safety and efficacy"IV The first patient was enrolled and the first dose was administered in the Phase I clinical study.IV Entering the substantive clinical research stage.
Healthgen Biotech
· Aflibercept® Phase IV Clinical Trial Completes First Dose Administration
Healthgen Biotech
· Aflibercept® Phase IV Clinical Trial Completes First Dose Administration
Healthgen Biotech
· Aflibercept® Phase IV Clinical Trial Completes First Dose Administration
Recently, Healthgen Biotech's recombinant human albumin (rice) Oufumin® "In Hypoalbuminemia and/or insufficient blood volume requiring emergency treatment in patients for safety and efficacy"IV The first patient was enrolled and the first dose was administered in the Phase I clinical study.IV Entering the substantive clinical research stage.
Century Healthcare
· Completed by multiple hospitalsInnermedical's Endoscopic Surgery
Century Healthcare
· Completed by multiple hospitalsInnermedical's Endoscopic Surgery
Recently, Taiyuan Aier Eye Hospital in Shanxi Province completed the first case of cataract surgery using the Wan Shi An lens in China.®Ultra-EDoFExtended Depth of Focus Intraocular Lens Implantation Surgery; Beijing Huaxia People's Eye Hospital Completes the First Batch in China for Wan Shi An®Ultra-EDoF Implantation Surgery of Artificial Crystalline Lens; Zhengzhou Apex Eye Hospital Implants the First Diffractive TypeEDoFIntraocular Lens (VisionEase)®Ultra-EDoF), etc.
Innermedical
· "Gemini" Lands at Macao Union Hospital, Supporting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Supporting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Supporting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Supporting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical"Gemini" Mini Probe Ultrasound Endoscope Officially Launched at Beijing Union Medical College Hospital Macao Medical Center, Injecting Innovative Momentum into the High-Quality Development of Macao and Guangdong-Hong Kong-Macao Greater Bay Area Healthcare.
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries of China’s Ministry of Industry and Information Technology, National Health Commission, and National Medical Products Administration, was officially launched. The project is led by West China Hospital of Sichuan University as the lead hospital, with Innermedical as the lead enterprise, coordinating efforts with 13 participating hospitals and 12 cooperative hospitals.
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries of China’s Ministry of Industry and Information Technology, National Health Commission, and National Medical Products Administration, was officially launched. The project is led by West China Hospital of Sichuan University as the lead hospital, with Innermedical as the lead enterprise, coordinating efforts with 13 participating hospitals and 12 cooperative hospitals.
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries of China’s Ministry of Industry and Information Technology, National Health Commission, and National Medical Products Administration, was officially launched. The project is led by West China Hospital of Sichuan University as the lead hospital, with Innermedical as the lead enterprise, coordinating efforts with 13 participating hospitals and 12 cooperative hospitals.
TGI
· Professor Zhigang Tian, Founder of TGI, Invited to Attend BIOCHINA2026 Conference
TGI
· Professor Zhigang Tian, Founder of TGI, Invited to Attend BIOCHINA2026 Conference
3Month12Day~14Day,BIOCHINA 2026The 11th EMBIS Biotechnology Exhibition was held in Suzhou.Leading Scholar in the International Immunology Field, Founder of TGIProfessor Tian Zhigang Invited to Three Core Forums.
Kash Bio
· Debut at 2026 CACLP
Kash Bio
· Debut at 2026 CACLP
Kash Bio
· Debut at 2026 CACLP
Kash Bio
· Debut at 2026 CACLP
3Month21To23On [date], the 25th China International Exhibition for Laboratory Medicine, Blood Transfusion Instruments, and Reagents was held in Xiamen. Kaishi Biotech, as a leading company in China,CDMOService providers, with multiple core achievements, made a significant appearance.
HaploX
· Exclusive Strategic Cooperation Reached with Healthgen Biotech
HaploX
· Exclusive Strategic Cooperation Reached with Healthgen Biotech
HaploX
· Exclusive Strategic Cooperation Reached with Healthgen Biotech
HaploX
· Exclusive Strategic Cooperation Reached with Healthgen Biotech
Recently,HaploX and WeiYi Biotech Exclusive Strategic Cooperation Signing Ceremony Successfully Held. This cooperation重磅推出“Fully Enclosed Zero-Contamination Medium-to-High Throughput Sequencing Solution”。
Tainuo Maibo
· New Drug for Preventing Infant RSV Infection - Rezubivimab Accelerates Market Launch Process
Tainuo Maibo
· New Drug for Preventing Infant RSV Infection - Rezubivimab Accelerates Market Launch Process
Tainuo Maibo
· New Drug for Preventing Infant RSV Infection - Rezubivimab Accelerates Market Launch Process
Tainuo Maibo
· New Drug for Preventing Infant RSV Infection - Rezubivimab Accelerates Market Launch Process
3Month2Recently, the recombinant long-acting anti-respiratory syncytial virus fully human monoclonal antibody — Riatvimab injection, developed by Zhuhai Tanomab, has been officially included in the priority review and approval process of the Center for Drug Evaluation of the National Medical Products Administration.
03
Approval Status of New Drugs and Devices from Invested Companies
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yuyan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Circode Biotech
· HM2003 Injection Receives FDA Clinical Trial Approval and Pediatric Rare Disease Designation
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yuyan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Circode Biotech
· HM2003 Injection Receives FDA Clinical Trial Approval and Pediatric Rare Disease Designation
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yuyan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yuyan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yuyan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Circode Biotech
· HM2003 Injection Receives FDA Clinical Trial Approval and Pediatric Rare Disease Designation
Circode Biotech
· HM2003 Injection Receives FDA Clinical Trial Approval and Pediatric Rare Disease Designation
3 Month11 Day,Huanma BiotechAnnouncing its independently developed second core annularRNAInnovative Drugs HM2003 Injection solution officially approved by the U.S. Food and Drug Administration (FDA) Clinical Trial Permit.
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
3Month16Day,Hannuo Medical's Self-Developed Core Product of Extracorporeal Membrane Oxygenation System"Disposable Membrane Oxygenator" Officially Approved by the U.S. Food and Drug Administration (FDA) of510(k)Access Permit.
Reindeer Bio
· CAR-T Drug Idecabtagene Vicleucel Injection for the Treatment of 2/3 Line Multiple Myeloma Clinical Trial Application Receives Implied Consent from Japan's PMDA
Reindeer Bio
· CAR-T Drug Idecabtagene Vicleucel Injection for the Treatment of 2/3 Line Multiple Myeloma Clinical Trial Application Receives Implied Consent from Japan's PMDA
Reindeer Bio
· CAR-T Drug Idecabtagene Vicleucel Injection for the Treatment of 2/3 Line Multiple Myeloma Clinical Trial Application Receives Implied Consent from Japan's PMDA
Reindeer Bio
· CAR-T Drug Idecabtagene Vicleucel Injection for the Treatment of 2/3 Line Multiple Myeloma Clinical Trial Application Receives Implied Consent from Japan's PMDA
3Month24The other day, IASO Biotherapeutics announcedIts independently developed fully human targetedBCMA CAR-TCell therapy product Idecabtagene Vicleucel Injection (Fucaso) Clinical trial application has received tacit approval from Japan's Pharmaceuticals and Medical Devices Agency.
Lingshi Zhiyuan
· World's First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
Lingshi Zhiyuan
· World's First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
Lingshi Zhiyuan
· World's First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
Lingshi Zhiyuan
· World's First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
3Month12Day, Spirit BiotechES502Injection Solution ObtainedFDAApprovalIPhase clinical trial, used for treatingRAS G12VPatients with advanced solid tumors harboring mutations.
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone and Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13The other day, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that the company's self-developed1Class-original Innovative DrugCS08399Tablets for the treatment of methylthioadenosine phosphorylase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone and Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13The other day, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that the company's self-developed1Class-original Innovative DrugCS08399Tablets for the treatment of methylthioadenosine phosphorylase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone and Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone and Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13The other day, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that the company's self-developed1Class-original Innovative DrugCS08399Tablets for the treatment of methylthioadenosine phosphorylase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
04
Honors of Invested Enterprises
Selected for the 11th Batch of the "Directory of Excellent Domestic Medical Device Products"
· BIOPSEE® Beixi® Confocal Microendoscope, BIOPSEE® Beixi® Ultra-thin Probe-type
Selected for the 11th Batch of the "Directory of Excellent Domestic Medical Device Products"
· BIOPSEE® Beixi® Confocal Microendoscope, BIOPSEE® Beixi® Ultra-thin Probe-type
Selected as a key specialized and innovative small and medium-sized enterprise in Zhejiang Province by the Zhejiang Provincial Department of Economy and Information Technology for 2026 ("Key Provincial Specialized Enterprise").
· Hangzhou Huamai, Nylong Biotech
Selected as a key specialized and innovative small and medium-sized enterprise in Zhejiang Province by the Zhejiang Provincial Department of Economy and Information Technology for 2026 ("Key Provincial Specialized Enterprise").
· Hangzhou Huamai, Nylong Biotech
Awarded by the National Center for ADR Monitoring as an Outstanding Pharmaceutical, Medical Device, and Cosmetic Enterprise in ADR Monitoring and Evaluation Work in 2025
· Real Biotech
Awarded by the National Center for ADR Monitoring as an Outstanding Pharmaceutical, Medical Device, and Cosmetic Enterprise in ADR Monitoring and Evaluation Work in 2025
· Real Biotech
Debut at AACR 2026: Poster Presentation of Two Research Achievements
· TGI
Debut at AACR 2026: Poster Presentation of Two Research Achievements
· TGI
AwardedThird Prize in the First Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition
· Huayuan Regenerative Medicine
"Selected as One of the 'Top Ten Research Studies in Breast Cancer in 2025'"
· Huahao Zhongtian's Utidelone in the Treatment of Brain Metastases from Breast Cancer
HonorAwarded 2026 Forbes China Industry Development Leading Enterprise
· Aomo Pharmaceuticals, Genuine Biotech
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
05
Yifeng Honor
AwardedThird Prize in the First Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition
· Huayuan Regenerative Medicine
"Selected as One of the 'Top Ten Research Studies in Breast Cancer in 2025'"
· Huahao Zhongtian's Utidelone in the Treatment of Brain Metastases from Breast Cancer
"Selected as One of the 'Top Ten Research Studies in Breast Cancer in 2025'"
· Huahao Zhongtian's Utidelone in the Treatment of Brain Metastases from Breast Cancer
HonorAwarded 2026 Forbes China Industry Development Leading Enterprise
· Aomo Pharmaceuticals, Genuine Biotech
HonorAwarded 2026 Forbes China Industry Development Leading Enterprise
· Aomo Pharmaceuticals, Genuine Biotech
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
05
Yifeng Honor
06
Yifeng Chronicle
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th EMBIO Biotechnology Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.Yifeng Capital CEO Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Synergy: 'Collaborative' Policies, Capital, and Innovation."
06
Yifeng Chronicle
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th EMBIO Biotechnology Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.Yifeng Capital CEO Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Synergy: 'Collaborative' Policies, Capital, and Innovation."
06
Yifeng Chronicle
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th EMBIO Biotechnology Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.Yifeng Capital CEO Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Synergy: 'Collaborative' Policies, Capital, and Innovation."
✦
Recommended Reading
✦
NorthX Life Sci. STAR IPO
✦
Recommended Reading
✦
NorthX Life Sci. STAR IPO
NorthX Life Sci. STAR IPO
Healthgen Biotech STAR Market IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Healthgen Biotech Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech STAR Market IPO
Ten Years of Honing a Sword – Its Blade Will Surely Gleam Upon Unsheathing
Athenex Pharma's STAR Market IPO
Looking forward to your
Share
Like
In
Healthgen Biotech STAR Market IPO
Healthgen Biotech STAR Market IPO
Healthgen Biotech STAR Market IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Healthgen Biotech Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech STAR Market IPO
Ten Years of Honing a Sword – Its Blade Will Surely Gleam Upon Unsheathing
Athenex Pharma's STAR Market IPO
Looking forward to your
Share
Like
In